Department of Orthopaedic Surgery, Division of Musculoskeletal Oncology, Cancer Stem Cell Laboratory, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Clin Cancer Res. 2015 Jul 1;21(13):2889-91. doi: 10.1158/1078-0432.CCR-14-3069. Epub 2015 Jan 21.
Geller and colleagues report that adjuvant chemotherapy affected the adequacy of osteosarcoma local surgical control. Exogenous bone morphogenetic protein-2 (BMP-2) did not increase local recurrence, but the limited theoretical benefits of BMP-2 for a subset of patients with osteosarcoma may not justify the systemic and long-term risks.
盖勒（Geller）及其同事报告称，辅助化疗影响了骨肉瘤局部手术控制的充分性。外源性骨形态发生蛋白-2（BMP-2）并未增加局部复发，但 BMP-2 对少数骨肉瘤患者的理论益处有限，可能无法证明其全身和长期风险是合理的。
